Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 17;29:3. doi: 10.1186/s12929-022-00787-1

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 6 — Sp1 inhibits CD44 expression in lung cancer. Samples of A549, H1299, E2-A549 and A549-T24 cells with or without Sp1 overexpression or knockdown were used to study the levels of Sp1 and CD44 by Western blotting with the indicated antibodies (A, B). Samples of A549, E2-A549 (C) and A549-T24 (D) cells were used to study the levels of E-cadherin, vimentin, CD44 and β-catenin by Western blotting with the indicated antibodies. The migration (E, F, middle panel) and invasion (E, F, right panel) abilities of A549 cells with or without CD44 knockdown (E) or overexpression (F) were studied by a chamber assay. GFP and GFP-Sp1 were overexpressed in A549 cells with or without E2 treatment and then injected into SCID mice via the tail vein for 5 weeks. Mice were sacrificed for H&E staining (G, a). The level of GFP-Sp1 was studied by Western blotting with an anti-Sp1 antibody (G, b). The tumor area was measured by ImageJ, and a statistical assay was performed (G, c). The results of three independent experiments were quantitated, and statistical analysis was performed with a t test; *p < 0.05, **p < 0.01, ***p < 0.005